BR112015008113A2 - novo processo para preparar compostos para uso no tratamento de câncer. - Google Patents

novo processo para preparar compostos para uso no tratamento de câncer.

Info

Publication number
BR112015008113A2
BR112015008113A2 BR112015008113A BR112015008113A BR112015008113A2 BR 112015008113 A2 BR112015008113 A2 BR 112015008113A2 BR 112015008113 A BR112015008113 A BR 112015008113A BR 112015008113 A BR112015008113 A BR 112015008113A BR 112015008113 A2 BR112015008113 A2 BR 112015008113A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
new process
prepare compounds
prepare
compounds
Prior art date
Application number
BR112015008113A
Other languages
English (en)
Other versions
BR112015008113B1 (pt
Inventor
Srivastava Amit
C Sowell Gregory
Yang Jason
Pfeiffer Matthew
Guz Nathan
Naganathan Sriram
Bostick Tracy
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BR112015008113A2 publication Critical patent/BR112015008113A2/pt
Publication of BR112015008113B1 publication Critical patent/BR112015008113B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112015008113-4A 2012-10-12 2013-10-14 Novo processo para preparar compostos para uso no tratamento de câncer BR112015008113B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
US61/713,104 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
BR112015008113A2 true BR112015008113A2 (pt) 2017-07-04
BR112015008113B1 BR112015008113B1 (pt) 2022-05-24

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008113-4A BR112015008113B1 (pt) 2012-10-12 2013-10-14 Novo processo para preparar compostos para uso no tratamento de câncer

Country Status (31)

Country Link
US (4) US9771347B2 (pt)
EP (1) EP2909188B1 (pt)
JP (2) JP6300042B2 (pt)
KR (1) KR102204520B1 (pt)
CN (2) CN108948043B (pt)
AU (1) AU2013328929B2 (pt)
BR (1) BR112015008113B1 (pt)
CA (1) CA2889466C (pt)
CL (1) CL2015000926A1 (pt)
CR (2) CR20200237A (pt)
EA (1) EA030613B1 (pt)
ES (1) ES2671502T3 (pt)
GE (1) GEP201706690B (pt)
HK (2) HK1213567A1 (pt)
HR (1) HRP20180670T1 (pt)
IL (1) IL238116B (pt)
IN (1) IN2015DN03928A (pt)
MA (1) MA38085B1 (pt)
MX (2) MX2015004660A (pt)
MY (1) MY186549A (pt)
NZ (1) NZ706723A (pt)
PE (3) PE20151494A1 (pt)
PH (1) PH12015500785A1 (pt)
PL (1) PL2909188T3 (pt)
SA (1) SA515360271B1 (pt)
SG (1) SG11201502795VA (pt)
SI (1) SI2909188T1 (pt)
TR (1) TR201807861T4 (pt)
UA (1) UA115455C2 (pt)
WO (1) WO2014059422A1 (pt)
ZA (1) ZA201502349B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ706723A (en) 2012-10-12 2018-07-27 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
TWI795344B (zh) 2015-06-30 2023-03-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
WO2022192202A1 (en) 2021-03-09 2022-09-15 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
JP2024514112A (ja) 2021-04-06 2024-03-28 ジェネンテック， インコーポレイテッド ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CN1094487C (zh) 1994-04-01 2002-11-20 盐野义制药株式会社 肟衍生物和含有其作为活性成分的杀菌剂
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
ATE344791T1 (de) * 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
KR20010101203A (ko) 1998-12-15 2001-11-14 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제의 이식 조직 거부를 예방하기 위한 용도
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
HUP0104844A3 (en) 1998-12-22 2003-05-28 Warner Lambert Co Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
IL144103A0 (en) 1999-01-07 2002-05-23 Warner Lambert Co Antiviral method using mek inhibitors
OA11746A (en) 1999-01-13 2005-05-13 Warner Lambert Co Benzoheterocycles and their use as MEK inhibitors.
WO2000042029A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
ATE309205T1 (de) 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
WO2001005391A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DE60005688T2 (de) 1999-07-16 2004-04-29 Warner-Lambert Co. Llc Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
HU230773B1 (hu) 1999-09-17 2018-03-28 Millennium Pharmaceuticals, Inc. Benzamidok és rokon Xa faktor inhibitorok
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
JP2004507518A (ja) * 2000-08-25 2004-03-11 ワーナー−ランバート・カンパニー・エルエルシー Ｎ−アリール−アントラニル酸及びその誘導体の製造法
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
MXPA04002539A (es) 2001-10-31 2004-05-31 Pfizer Prod Inc Combatientes de los receptores de la acetilcolina nicotinica en el tratamiento del sindrome de pierna inquietas.
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
PA8569201A1 (es) 2002-03-13 2004-05-21 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984573B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7314873B2 (en) 2002-06-11 2008-01-01 Merck & Co., Inc. (Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004218463B2 (en) 2003-03-03 2009-07-16 Array Biopharma, Inc. p38 inhibitors and methods of use thereof
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05013227A (es) 2003-06-20 2006-03-09 Celltech R&D Ltd Derivados de tienopiridona como inhibidores de cinasa.
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
BRPI0412851A (pt) 2003-07-24 2006-10-03 Warner Lambert Co benzamidazóis de n-metila-substituìdos
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293017B2 (en) 2003-11-19 2010-08-19 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
WO2005058887A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
US7956191B2 (en) 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN110668988A (zh) * 2005-10-07 2020-01-10 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
NZ706723A (en) 2012-10-12 2018-07-27 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
BR112016017648B1 (pt) 2014-02-07 2021-01-19 Sumitomo Chemical Company, Limited método para produção de (r)-1,1,3-trimetil-4-aminoindano
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
HRP20180670T1 (hr) 2018-07-13
US9771347B2 (en) 2017-09-26
BR112015008113B1 (pt) 2022-05-24
US20170349569A1 (en) 2017-12-07
CN108948043A (zh) 2018-12-07
US20200392104A1 (en) 2020-12-17
ZA201502349B (en) 2019-12-18
CR20150245A (es) 2015-11-19
HK1213567A1 (zh) 2016-07-08
US11414396B2 (en) 2022-08-16
AU2013328929B2 (en) 2018-01-04
PL2909188T3 (pl) 2018-08-31
JP2018052973A (ja) 2018-04-05
JP2015533175A (ja) 2015-11-19
ES2671502T3 (es) 2018-06-06
MY186549A (en) 2021-07-26
MX2015004660A (es) 2015-08-07
US10239858B2 (en) 2019-03-26
CR20200237A (es) 2020-07-26
MX2020005533A (es) 2020-10-12
PE20191818A1 (es) 2019-12-27
EA030613B1 (ru) 2018-08-31
UA115455C2 (uk) 2017-11-10
IN2015DN03928A (pt) 2015-10-02
GEP201706690B (en) 2017-06-26
KR102204520B1 (ko) 2021-01-20
CN104837826A (zh) 2015-08-12
CA2889466A1 (en) 2014-04-17
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
EP2909188A1 (en) 2015-08-26
CA2889466C (en) 2021-09-14
EA201590700A1 (ru) 2015-09-30
EP2909188B1 (en) 2018-03-07
AU2013328929A1 (en) 2015-04-30
WO2014059422A1 (en) 2014-04-17
PE20200387A1 (es) 2020-02-24
US20150210668A1 (en) 2015-07-30
KR20150067339A (ko) 2015-06-17
PH12015500785B1 (en) 2015-06-15
NZ706723A (en) 2018-07-27
CN104837826B (zh) 2018-07-27
CN108948043B (zh) 2021-05-04
PE20151494A1 (es) 2015-11-06
SA515360271B1 (ar) 2016-05-19
CL2015000926A1 (es) 2015-08-28
US10793541B2 (en) 2020-10-06
IL238116B (en) 2018-06-28
HK1213878A1 (zh) 2016-07-15
MA38085A1 (fr) 2018-08-31
SI2909188T1 (en) 2018-07-31
JP6300042B2 (ja) 2018-03-28
TR201807861T4 (tr) 2018-06-21
SG11201502795VA (en) 2015-05-28
PH12015500785A1 (en) 2015-06-15

Similar Documents

Publication Publication Date Title
BR112015008113A2 (pt) novo processo para preparar compostos para uso no tratamento de câncer.
BR112014032105A2 (pt) método para o tratamento de câncer
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
BR112014016732A8 (pt) processos para tratar lama vermelha
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
BR112014015994A2 (pt) processo.
BR112014028728A2 (pt) processo de tratamento de cabelo
BR112014012880A2 (pt) tratamento imunogênico do câncer
BR112014026796A2 (pt) processo
BR112014028396A2 (pt) processo de isolamento/purificação de célula de tumor e métodos para uso da mesma
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
BR112015007975A2 (pt) processo para preparar continuamente tetrapolímeros, e tetrapolímero
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
BR112014026795A2 (pt) composição cosmética , processo cosmético para tratar a matéria queratínica e uso de uma composição cosmética.
BR112015002464A2 (pt) processo para a preparação de carbamat-benzoxazinonas, carbamat-benzoxazinonas e utilização das carbamat-benzoxazinonas
BR112014031259A2 (pt) composição cosmética e processo para maquiagem.
BR112013018942A2 (pt) processo para o preparo de 4-amino-3-cloro-5-fluro-6(substituído) picolinatos.
BR112014009684A2 (pt) processo para preparar polímeros, polímero e uso de polímeros
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014022694A2 (pt) novos métodos e composições para o tratamento de doença
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
BR112014026565A2 (pt) formulação, uso de uma formulação, e, processo para produzir uma formulação

Legal Events

Date Code Title Description
B25I Requirement for requested change of headquarter

Owner name: EXELIXIS, INC. (US)

B25C Requirement related to requested transfer of rights

Owner name: EXELIXIS, INC. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: EXELIXIS, INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.9 NA RPI NO 2602 DE 17/11/2020 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25B Requested transfer of rights rejected

Owner name: EXELIXIS, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870200096240 DE 31/07/2020, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2603, DE 24/11/2020.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 401/04 , C07D 498/04

Ipc: C07D 401/04 (2006.01), C07D 498/04 (2006.01), ...

B25G Requested change of headquarter approved

Owner name: EXELIXIS, INC. (US)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: EXELIXIS, INC. (US) ; GENENTECH, INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/10/2013, OBSERVADAS AS CONDICOES LEGAIS